Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency

NEXT STORY
DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies
PREV STORY
Policy thought-leaders, Don Drummond and Duncan Sinclair, release long-term care report seeking to reshape the future for Canadian seniors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa® (patiromer) With or Without Food

Updated label may allow for increased dosing flexibility for patients with hyperkalemia (elevated blood ...

author_avatar
NASDAQ Market News

Novavax to Participate in the Citi 12th Annual Biotech Conference

GAITHERSBURG, Md., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the ...

author_avatar
NASDAQ Market News

Shire Granted EU Marketing Authorization for Veyvondi® for Adults With Von Willebrand Disease

SHIRE GRANTED EU MARKETING AUTHORIZATION FOR VEYVONDI® [VONICOG ALFA, RECOMBINANT VON WILLEBRAND FACTOR] FOR ...

author_avatar
NASDAQ Market News